Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model
- 1 September 1989
- Vol. 64 (5) , 1117-1122
- https://doi.org/10.1002/1097-0142(19890901)64:5<1117::aid-cncr2820640525>3.0.co;2-r
Abstract
Data obtained from 209 patients who entered different prospective randomized antiemetic trials were analyzed to establish the prognostic value of some variables on the control of cisplatin-induced emesis. The antiemetic regimens evaluated included the following: metoclopramide (M) at 1, 2, and 4 mg/kg total dose and a combination of M (4 mg/kg) with dexamethasone (D) (40 mg). Vomiting lasting more than I hour (no protection [NP]) was the endpoint selected for the analysis. A logistic model carried out, first on the 110 subjects receiving the M + D regimen and then on the whole sample, selected sex (P = 0.0001), Eastern Cooperative Oncology Group performance status (PS) (P = 0.006), and age (P = 0.01) among the six factors considered. Since the prognostic value of these variables is mostly related to their interaction, three major risk classes were identified. The corresponding NP rates were 26.3%, 42.4%, and 70.8% for the low-risk, intermediate-risk, and high-risk groups, respectively (P = 0.000002). Except for the lowest M level, the observed NP rates were significantly associated to the risk classes, whereas the antiemetic regimen influenced the antiemetic outcome only in the low-risk class. Regardless of the regimen employed, certain patient characteristics, such as sex, PS, and age, significantly affect cisplatin-related emesis and should be carefully considered in planning further studies.This publication has 21 references indexed in Scilit:
- Optimum Management of Nausea and Vomiting in Cancer ChemotherapyDrugs, 1987
- Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.Journal of Clinical Oncology, 1987
- High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.Journal of Clinical Oncology, 1985
- Antiemetic Efficacy of Moderately High-Dose Metoclopramide in Patients Receiving Varying Doses of CisplatinOncology, 1985
- Advances in anti-emetic therapyCancer Treatment Reviews, 1984
- Methodologic issues in trials of antiemetics.Journal of Clinical Oncology, 1984
- Randomized open cross-over trial between Metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomitingEuropean Journal of Cancer and Clinical Oncology, 1984
- ANTIEMETIC DRUG COMBINATIONS IN ADVANCED CANCERThe Lancet, 1982
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981
- Toxicity of Cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydrationCancer, 1980